The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P+GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC).

Mahdi  Gharaibeh

No Relationships to Disclose

Ali  McBride

No Relationships to Disclose

J. Lyle  Bootman

Stock and Other Ownership Interests  - Walgreens

Consulting or Advisory Role - Merck

Lee D.  Cranmer

Speakers' Bureau - Bristol-Myers Squibb; Genentech (I)

Research Funding - Amgen; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Merck; Prometheus; Threshold Pharmaceuticals

Ivo  Abraham

Leadership - Matrix45; Matrix45 (I)

Stock and Other Ownership Interests  - Matrix45; Matrix45 (I)